EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting UCHL3 attenuates pathological markers in neuronal models of Huntington’s disease

Hasan Ishtayeh, Elena Battistoni, Sharon Pochtar, Tyne L M McHugh, Kizito-Tshitoko Tshilenge, Brian Rossmiller, Fatima Amer-Sarsour, Yevgeny Berdichevsky, Noam Muchtar, Miguel Weil, Lisa M Ellerby iD, Avraham Ashkenazi iD

Brain · 2026

DOI: 10.1093/brain/awag028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, 2026. Verfasst von Hasan Ishtayeh und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cellular, Developmental, and Regenerative Biology, Gray School of Medical Sciences, Gray Faculty of Medical and Health Sciences, Tel Av…. Hauptthemen laut MEDLINE: Huntington Disease, Neurons, Ubiquitin Thiolesterase. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Koret\Taube Global Collaboration in Neurodegenerative Diseases, Aufzien Center for the Prevention and Treatment of Parkinson's disease, Healthy Longevity Research Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease with a well-characterized genetic etiology of a CAG expansion mutation in the huntingtin (HTT) gene, yet it remains without a cure. The hallmark of HD is the accumulation of intraneuronal aggregates of mutant HTT protein and polyglutamine (polyQ)-containing fragments, which cause impaired proteostasis and is an important HD therapeutic target. Aggregate-prone protein clearance primarily occurs through the autophagy-lysosome pathway and the ubiquitin-proteasome system, both of which can be modulated by deubiquitinating enzymes (DUBs). This study investigates the role of the DUB ubiquitin C-terminal hydrolase L3 (UCHL3) in modulating polyQ-mediated aggregation and toxicity. UCHL3 has previously been identified as a potential therapeutic target in cancer. We utilize HD models, including primary mouse neurons, patient fibroblasts, and patient-derived medium spiny neurons (MSN), which are the most vulnerable to HTT polyQ toxicity. Genetic lowering of UCHL3 decreased polyQ aggregates and increased autophagosome-lysosome fusion events. This was accompanied by STAT3 induction, which protects against neuronal proteotoxic stress. Furthermore, treatment with a small-molecule inhibitor of UCHL3 recapitulated the effects of UCHL3 lowering and attenuated pathological markers in HD MSN. These results provide a foundation for further exploration of UCHL3 inhibitors in the context of HD and underscore the biological connection between cancer and neurodegeneration for drug repurposing strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Huntington DiseaseNeuronsUbiquitin ThiolesteraseAnimalsMiceHumansHuntingtin ProteinDisease Models, AnimalAutophagySTAT3 Transcription FactorPeptidesMice, TransgenicProteotoxic Stress

Stichwörter der Autor:innen

Huntington’s diseaseaggregate-prone proteinsautophagyinduced pluripotent stem cells

Substanzen

Ubiquitin ThiolesteraseHuntingtin ProteinpolyglutamineSTAT3 Transcription FactorPeptides

Autor:innen und Institutionen

  • Department of Cellular, Developmental, and Regenerative Biology, Gray School of Medical Sciences, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.
  • Buck Institute for Research on Aging, Novato, CA 94945, USA.
  • Sagol School of Neuroscience, Tel Aviv University, Tel Aviv 6997801, Israel.
  • Leonard Davis School of Gerontology, University of Southern California, Los Angeles, CA 90089, USA.
  • The Shmunis School of Biomedicine and Cancer Research, The George S. Wise Faculty for Life Sciences, Tel Aviv 6997801, Israel.

ORCID-Profile: Lisa M Ellerby, Avraham Ashkenazi

Förderung

  • Koret\Taube Global Collaboration in Neurodegenerative Diseases
  • Aufzien Center for the Prevention and Treatment of Parkinson's disease
  • Healthy Longevity Research Center
  • Council for Higher Education
  • NIH HHS
  • NIA NIH HHS
  • Valley Foundation

Zitieren

APA

Ishtayeh, H., Battistoni, E., Pochtar, S., McHugh, T. L. M., Tshilenge, K. T., Rossmiller, B., Amer-Sarsour, F., Berdichevsky, Y., Muchtar, N., Weil, M., Ellerby, L. M., & Ashkenazi, A. (2026). Targeting UCHL3 attenuates pathological markers in neuronal models of Huntington’s disease. Brain. https://doi.org/10.1093/brain/awag028

Vancouver

Ishtayeh H, Battistoni E, Pochtar S, McHugh TLM, Tshilenge KT, Rossmiller B, et al. Targeting UCHL3 attenuates pathological markers in neuronal models of Huntington’s disease. Brain. 2026. doi:10.1093/brain/awag028

BibTeX
@article{Ishtayeh2026,
  author = {Ishtayeh, Hasan and Battistoni, Elena and Pochtar, Sharon and McHugh, Tyne L M and Tshilenge, Kizito-Tshitoko and Rossmiller, Brian and Amer-Sarsour, Fatima and Berdichevsky, Yevgeny and Muchtar, Noam and Weil, Miguel and Ellerby, Lisa M and Ashkenazi, Avraham},
  title = {Targeting UCHL3 attenuates pathological markers in neuronal models of Huntington’s disease},
  journal = {Brain},
  year = {2026},
  doi = {10.1093/brain/awag028}
}
Kostenlos starten →